Biogen (BIIB) PT Lowered to $351 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.83 -0.39%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $351.00 (from $352.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
- Diversified Royalty Corp (DIV:CN) (BEVFF) PT Lowered to Cdn$4.75 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
